Skip to main content
Clinical Trials/JPRN-UMIN000005878
JPRN-UMIN000005878
Recruiting
未知

Clinico-pathological study on the effectiveness of cepharanthin on the prevention of destruction of acinar structure in Sjogren's syndrome patients - Effectiveness of cepharanthin on the acinar structure

Department of Oral Medicine, Institute of Health Biosciences, The University of Tokushima Graduate Faculty of Dentistry0 sites10 target enrollmentJuly 31, 2011

Overview

Phase
未知
Intervention
Not specified
Conditions
Sjogren&#39
Sponsor
Department of Oral Medicine, Institute of Health Biosciences, The University of Tokushima Graduate Faculty of Dentistry
Enrollment
10
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 31, 2011
End Date
December 1, 2012
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Oral Medicine, Institute of Health Biosciences, The University of Tokushima Graduate Faculty of Dentistry

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Secondary Sjogren's syndrome, Xerostomia due to aging

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
An investigation of the clinical effectiveness of fixing the probe to the skin during ultrasound-guided central venous cannulation.Patients undergoing central venous cannulation
JPRN-UMIN000009237Hirosaki University Graduate School of Medicine280
Active, not recruiting
Not Applicable
Clinical study of the safety and effectiveness of two hyaluronic acid injectable products (MaiLi Precise® and MaiLi Define®) as fillers in the treatment of lip thinness and wrinkles around the mouth
ISRCTN30768206Sinclair Pharma68
Completed
Not Applicable
Clinical study of the safety and effectiveness of the use of two hyaluronic acid injectable products (MaiLi Precise® and MaiLi Define®) in the treatment of facial skin depressions of the mid-faceFor MaiLi Precise® treatment: mild to moderate nasolabial folds and/or subjects with mild to moderate tear trough. For MaiLi Define® treatment: moderate to severe nasolabial folds and/or moderate to severe marionette lines.Skin and Connective Tissue Diseases
ISRCTN10761529Sinclair Pharma68
Not yet recruiting
Phase 1
Role of sarvakalpa ghan vati in liver disease.Health Condition 1: K768- Other specified diseases of liver
CTRI/2020/06/025733Dr Zeba Malik
Recruiting
Phase 3
Evaluation of the effect of TauroLock™ and piperacillin-tazobactam in secondary prophylaxis of Port-Catheter infection.Infection due to port catheter.Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts
IRCT20180309039013N1Shiraz University of Medical Sciences50